Johnson & Johnson (NYSE:JNJ) Shares Acquired by Asio Capital LLC

Asio Capital LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,082 shares of the company’s stock after buying an additional 463 shares during the period. Asio Capital LLC’s holdings in Johnson & Johnson were worth $4,929,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. IFS Advisors LLC lifted its stake in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares in the last quarter. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at approximately $35,000. Mowery & Schoenfeld Wealth Management LLC grew its position in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson in the third quarter worth $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. Guggenheim raised their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Wells Fargo & Company cut their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Bank of America decreased their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Wolfe Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.44.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $150.63 on Wednesday. The business has a 50 day simple moving average of $147.81 and a 200 day simple moving average of $156.12. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $362.65 billion, a price-to-earnings ratio of 22.65, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.29 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.29%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.